MGMT and central nervous system cancer: Mutant IDH1 was shown to promote the glioma cytosine–phosphate–guanine (CpG) island methylator phenotype (G-CIMP) in gliomas, which are often characterized by the epigenetic silencing of MGMT [57,58].